Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 μg desogestrel and either 30 μg or 20 μg ethinyl oestradiol

No abstract is available for this paper.

• Publication year

  1993

• Venue

  BJOG: An International Journal of Obstetrics & Gynaecology

• Publication date

  1993-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1471-0528.1993.tb14309.x
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral contraceptive use and breast cancer risk: a meta‐analysis of variations with age at diagnosis, parity and total duration of oral contraceptive use

  1992cited by this paper
• Phase III clinical trial with a new oral contraceptive containing 150 μg desogestrel and 20 μg ethinylestradiol

  1991cited by this paper
• Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case‐control study

  1991cited by this paper
• Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study.

  1990cited by this paper
• The patient's reaction to side effects of oral contraceptives.

  1989cited by this paper
• Bleeding patterns with low-dose, monophasic oral contraceptives.

  1989cited by this paper
• Multicenter Trial of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Desogestrel

  1988cited by this paper
• The association between vaginal bleeding patterns and reasons for discontinuation of contraceptive use.

  1988cited by this paper
• Effects of the Oral Contraceptive Combination 0.150 mg Desogestrel + 0.020 mg Ethinylestradiol on Serum Lipids Including the HDL Subfractions

  1987cited by this paper
• Task Force on Long-acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction

  1987cited by this paper
• Effects of the Oral Contraceptive Combination 0.150 mg Desogestrel Plus 0.020 mg Ethinylestradiol on Carbohydrate Metabolism in Healthy Female Volunteers

  1987cited by this paper
• Effects of the Oral Contraceptive Combination 0.150 mg Desogestrel+0.020 mg Ethinylestradiol on Serum Lipids, SHBG, Glycosylated Proteins and Plasma Antithrombin III Activity in Healthy Women

  1987cited by this paper
• Pharmacodynamic Studies on Desogestrel Administered Alone and in Combination with Ethinylestradiol

  1985cited by this paper
• Oral contraceptives, lipids and cardiovascular disease.

  1985cited by this paper
• Reduced plasminogen activator content of the endometrium in oral contraceptive users.

  1983cited by this paper
• Effects of desogestrel and levonorgestrel in low-dose oestrogen oral contraceptives on serum lipoproteins.

  1982cited by this paper
• Two oral contraceptives, efficacy, serum proteins, and lipid metabolism. A comparative multicentre study on a triphasic and a fixed dose combination.

  1982cited by this paper
• The morphologic response of the human endometrium to long-term treatment with progestational agents.

  1982cited by this paper
• Endometrial morphology and peripheral steroid levels in women with and without intermenstrual bleeding during contraception with the 300 microgram norethisterone (NET) minipill.

  1982cited by this paper
• Scandinavian Trial of an Oral Contraceptive Containing 0.150 Mg Desogestrel and 0.030 Mg Ethinylestradiol

  1982cited by this paper
• Oral contraceptives and cardiovascular disease (first of two parts).

  1981cited by this paper
• Discussion [of patterns of bleeding associated with the use of steroidal contraceptives].

  1980cited by this paper
• Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content.

  1980cited by this paper
• A RANDOMIZED DOUBLE‐BLIND TRIAL OF TWO LOW DOSE COMBINED ORAL CONTRACEPTIVES

  1979cited by this paper
• Oral contraceptives and nonfatal myocardial infarction.

  1978cited by this paper
• Distribution-Free Statistical Tests

  1968cited by this paper

• Understanding Problematic Bleeding When Using Contraception: Guidance for Clinicians

  2025cites this paper
• Efficacy of transcervical resection of polyp combined with levonorgestrel-releasing intrauterine system in the treatment of endometrial polyps: a randomized controlled trial

  2025cites this paper
• Mood disorders and hormonal status across women’s life: a narrative review

  2022cites this paper
• Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial

  2021cites this paper
• Short-Acting Hormonal Contraception: The Pills, the Patch, and the Rings

  2021cites this paper
• FSRH Guideline (January 2019) Combined Hormonal Contraception

  2018cites this paper
• [Effectiveness and use of hormonal contraceptives (except for intrauterine devices): CNGOF Contraception Guidelines].

  2018cites this paper
• Hémorragie génitale de la femme en dehors de la grossesse

  2017cites this paper
• Combined hormonal contraception and its effects on mood: a critical review

  2016cites this paper
• Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial.

  2016cites this paper
• Prescribing Medicines to Adolescent Women

  2015cites this paper
• Efficacy and Safety of a Combined Oral Contraceptive Containing Estradiol Valerate/Dienogest: Results from a Clinical Study Conducted in North America

  2014cites this paper
• A survey on Swiss women's preferred menstrual/withdrawal bleeding pattern over different phases of reproductive life and with use of hormonal contraception

  2014cites this paper
• The effects of oral contraceptives on SHBG and free testosterone and their relevance to premenstrual mood and sexual interest: A comparison of two triphasic formulations containing norgestimate and either 35μg or 25μg of ethinyl estradiol. By:

  2013cites this paper
• Contraception and Headache

  2013cites this paper
• Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: A pooled analysis of three studies conducted in North America and Europe

  2013cites this paper
• 20 µg versus >20 µg estrogen combined oral contraceptives for contraception.

  2013cites this paper
• Drug safety evaluation of desogestrel

  2013cites this paper
• Comparison of the pharmacologic and clinical profiles of new combined oral contraceptives containing estradiol

  2013cites this paper
• Oral contraceptives and the periodontium.

  2013cites this paper
• Safety Data and Beneficial Effects of the Combined Oral Contraceptive Ethinylestradiol 0.03 mg/Chlormadinone Acetate 2 mg (Belara®)

  2011cites this paper
• Types of progestogens in combined oral contraception: effectiveness and side-effects.

  2011cites this paper
• Oral Contraceptive Pills: Combinations, Dosages and the Rationale behind 50 Years or Oral Hormonal Contraceptive Development

  2011cites this paper
• Ontwikkelingen in anticonceptie

  2010cites this paper
• Efficacy of contraceptive methods: A review of the literature

  2010cites this paper
• Unscheduled bleeding in combined oral contraceptive users: focus on extended-cycle and continuous-use regimens

  2009cites this paper
• Effects of two combined oral contraceptives containing ethinyl estradiol 30 μg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure

  2009cites this paper
• Twenty or thirty microgram ethinyloestradiol in an oral contraceptive: Does it make a difference in the mind and the daily practise of gynaecologists and general practitioners?

  2009cites this paper
• Updates on Hormonal Contraceptives

  2009cites this paper
• Physiologic and psychologic symptoms associated with use of injectable contraception and 20 microg oral contraceptive pills.

  2008cites this paper
• The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 μg of ethinyl estradiol

  2007cites this paper
• THE ROLE OF DIGOXIN IN TREATING SYSTOLIC HEART FAILURE: AN UPDATE

  2007cites this paper
• Continuous Oral Contraceptives: Are Bleeding Patterns Dependent on the Hormones Given?

  2006cites this paper
• A Comparison of the Cycle Control, Safety, and Efficacy Profile of a 21-Day Regimen of Ethinylestradiol 20μg and Drospirenone 3mg with a 21-Day Regimen of Ethinylestradiol 20μg and Desogestrel 150μg

  2006cites this paper
• Efficacy and Safety of a Low-Dose 21-Day Combined Oral Contraceptive Containing Ethinylestradiol 20μg and Drospirenone 3mg

  2006cites this paper
• The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.

  2006cites this paper
• Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review.

  2005cites this paper
• Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial.

  2005cites this paper
• Twenty micrograms vs. >20 microg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials.

  2005cites this paper
• Bleeding Patterns After Immediate Initiation of an Oral Compared With a Vaginal Hormonal Contraceptive

  2005cites this paper
• Navigating the choice of available COC pills

  2004cites this paper
• Enhancing oral contraceptive success: the potential of new formulations.

  2004cites this paper
• Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone

  2004cites this paper
• Progestogens in combined oral contraceptives for contraception.

  2004cites this paper
• Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol.

  2003cites this paper
• Facteurs associés à la prise de poids chez les femmes utilisant des contraceptifs oraux : enquête par sondage réalisée en 2001 auprès de 1665 femmes

  2003cites this paper
• Improvement of quality of life in women using a low-dose desogestrel-containing contraceptive: results of an observational clinical evaluation

  2002cites this paper
• Gynecologic problems of the perimenopause: evaluation and treatment.

  2002cites this paper
• Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol.

  2002cites this paper
• Noncontraceptive Health Benefits of Oral Contraceptives

  2002cites this paper
• New developments in contraceptive drugs for use by women

  2002cites this paper
• To what extent do oral contraceptives influence mood and affect?

  2002cites this paper
• Current perspectives on oral contraceptive use.

  2001cites this paper
• Oral contraceptives and mood

  2001cites this paper
• Influence of two low-dose oral contraceptives on pulsatile gonadotropin secretion

  2001cites this paper
• Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial.

  2000cites this paper
• An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen.

  2000cites this paper
• Latin American experience with two low–dose oral contraceptives containing 30 μg ethinylestradiol/75 μg gestodene and 20 μg ethinylestradiol/150 μg desogestrel

  2000cites this paper
• Serum leptin concentrations in women taking oral contraceptives.

  1999cites this paper
• Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity

  1999cites this paper
• Contraceptive strategies for young women in the 21st century.

  1999cites this paper
• Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 μg ethinyl estradiol combined with 150 μg desogestrel or 75 μg gestodene

  1999cites this paper
• Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 μg and 35 μg estrogen preparations

  1999cites this paper
• Cardiovascular risks: perception versus reality.

  1999cites this paper
• The efficacy and tolerability of Valette: a postmarketing surveillance study.

  1999cites this paper
• Oral contraceptive estrogen dose considerations.

  1998cites this paper
• Oral contraceptive practice guidelines.

  1998cites this paper
• A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene.

  1998cites this paper
• A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.

  1997cites this paper
• A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles

  1997cites this paper
• 8 Contraception for the older woman

  1996cites this paper
• Long term sequelae of sex steroid treatment in the management of constitutionally tall stature.

  1995cites this paper
• A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.

  1995cites this paper